Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of a 2‑dose regimen of ProQuad (MMRV, manufactured with recombinant human albumin) in children in their second year of life
2007-002438-12Phase 3Completed
- Sponsor
- Sanofi Pasteur MSD S.N.C.
- Start
- Jul 2007
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of varicella virus vaccine in measles, mumps, rubella and 1 more, sponsored by Sanofi Pasteur MSD S.N.C. Primary endpoints: Safety profile of second dose of ProQuad (rHA) in second year of life and Safety profile of first dose of ProQuad (rHA) in second year of life. Started Jul 2007; status: completed.
02
Drugs
varicella virus vaccine
03
Conditions
measlesmumpsrubellachickenpox
Beyond the preview
Go deeper on 2007-002438-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002438-12.